Henk-Jan Schuurman
Research Subjects
Henk-Jan Schuurman has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
A. Alt
Immerge BioTherapeutics, Inc., Cambridge, MA, USA
2 shared publicationsAndrew C. Richards
Imutran Ltd (A Novartis Pharma AG Company), Cambridge, UK
2 shared publicationsBeverly J. Holmes
Imutran Ltd, A Novartis Pharma AG Company, Cambridge, UK
2 shared publicationsCharles Pally
2 shared publicationsChristos Papageorgiou
2 shared publicationsDavid J. G. White
2 shared publications
Latest Publications
- 11 June 2004
- Published by Wiley in Xenotransplantation
- Vol. 11 (4) , 332-339
Anti-pig antibody levels in non-human primates of various origin
- 11 June 2004
- Published by Wiley in Xenotransplantation
- Vol. 11 (4) , 332-339
Anti-pig antibody levels in non-human primates of various origin
- 1 March 2004
- Published by Wiley in Xenotransplantation
- Vol. 11 (2) , 210-215
Reduction of anti-Gal?1,3Gal antibodies by infusion of types 2 and 6 gal trisaccharides conjugated to poly-l-lysine
To investigate the specificity of anti-Galalpha1,3Gal (Gal) antibodies (Abs) with respect to Gal oligosaccharides of types 2 and 6, eight baboons received an intravenous infusion of either a poly-l-lysine conjugate of Gal type 2 (n = 5) or type 6 (n = 3), followed 48 h later by the alternative Gal type 6 or 2 conjugate, respectively. IgM Abs reactive to Gal type 2 were depleted by 80 to 89% by either Gal conjugate. IgM reactive to Gal type 6 was less efficiently depleted by the Gal type 2 conjugate (57% depletion) than the Gal type 6 (82% depletion). Gal-reactive IgG was depleted more slowly and less efficiently by either glycoconjugate (initially by only 28 to 54%). Our results indicate that the Gal type 6 conjugate depletes most anti-Gal IgM, but the Gal type 2 conjugate is less efficient in depleting anti-Gal IgM reactive with type 6. There remain small fractions of antibody that are unadsorbed, particularly of IgG, probably due to their low affinity and distribution in both the intra- and extra-vascular compartments.
- 1 March 2004
- Published by Wiley in Xenotransplantation
- Vol. 11 (2) , 210-215
Reduction of anti-Gal?1,3Gal antibodies by infusion of types 2 and 6 gal trisaccharides conjugated to poly-l-lysine
To investigate the specificity of anti-Galalpha1,3Gal (Gal) antibodies (Abs) with respect to Gal oligosaccharides of types 2 and 6, eight baboons received an intravenous infusion of either a poly-l-lysine conjugate of Gal type 2 (n = 5) or type 6 (n = 3), followed 48 h later by the alternative Gal type 6 or 2 conjugate, respectively. IgM Abs reactive to Gal type 2 were depleted by 80 to 89% by either Gal conjugate. IgM reactive to Gal type 6 was less efficiently depleted by the Gal type 2 conjugate (57% depletion) than the Gal type 6 (82% depletion). Gal-reactive IgG was depleted more slowly and less efficiently by either glycoconjugate (initially by only 28 to 54%). Our results indicate that the Gal type 6 conjugate depletes most anti-Gal IgM, but the Gal type 2 conjugate is less efficient in depleting anti-Gal IgM reactive with type 6. There remain small fractions of antibody that are unadsorbed, particularly of IgG, probably due to their low affinity and distribution in both the intra- and extra-vascular compartments.
- 16 December 2003
- Published by Wiley in Xenotransplantation
- Vol. 11 (1) , 101-106
Galα1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus
Abstract: Galα1,3Gal (Gal) is the first target in antibody‐mediated rejection of pig‐to‐non‐human primate xenograft. Its expression may vary between organs and constituents of organs. Gal expression was studied in pancreas, testis, spleen and thymus of 22 pigs, with ages ranging from 1 to 22 months. The immunoperoxidase technique using the biotinylated lectin, Griffonia simplicifolia (IB4), was used. In the pancreas, neither endocrine (islet cells) nor exocrine cells expressed Gal. The Sertoli cells in the testis were negative. The spleen capsule and trabeculae did not stain for Gal, although both splenic T and B lymphocytes expressed Gal (B > T). Thymocytes were weakly positive, whereas thymic epithelial cells were negative for Gal. No age‐related differences were seen in any tissues. Porcine islets of Langerhans, Sertoli cells, and the splenic and thymic structural frameworks did not express Gal, and therefore, should be relatively resistant to anti‐Gal antibody‐mediated rejection. The availability of pigs deficient in Gal as a source of islets may therefore not be beneficial in extending islet graft survival in non‐human primate models.
- 16 December 2003
- Published by Wiley in Xenotransplantation
- Vol. 11 (1) , 101-106
Galα1,3Gal expression on porcine pancreatic islets, testis, spleen, and thymus
Abstract: Galα1,3Gal (Gal) is the first target in antibody‐mediated rejection of pig‐to‐non‐human primate xenograft. Its expression may vary between organs and constituents of organs. Gal expression was studied in pancreas, testis, spleen and thymus of 22 pigs, with ages ranging from 1 to 22 months. The immunoperoxidase technique using the biotinylated lectin, Griffonia simplicifolia (IB4), was used. In the pancreas, neither endocrine (islet cells) nor exocrine cells expressed Gal. The Sertoli cells in the testis were negative. The spleen capsule and trabeculae did not stain for Gal, although both splenic T and B lymphocytes expressed Gal (B > T). Thymocytes were weakly positive, whereas thymic epithelial cells were negative for Gal. No age‐related differences were seen in any tissues. Porcine islets of Langerhans, Sertoli cells, and the splenic and thymic structural frameworks did not express Gal, and therefore, should be relatively resistant to anti‐Gal antibody‐mediated rejection. The availability of pigs deficient in Gal as a source of islets may therefore not be beneficial in extending islet graft survival in non‐human primate models.
- 10 June 2003
- Published by Wiley in Xenotransplantation
- Vol. 10 (4) , 293-299
Pathology of xenograft rejection: a commentary
Trends in solid organ xenograft pathology are presented, with the focus on pig‐to‐nonhuman primate models. A simplified classification of rejection is followed, including hyperacute rejection (HAR), acute humoral xenograft rejection (AHXR), and acute cellular xenograft rejection (ACXR). The main components in HAR are natural xenoreactive antibodies in combination with complement activation. This is evident from the prevention of HAR in recipients in whom either antibodies or complement activation is depleted or inhibited. However, these strategies generally fail to prevent AHXR, which occurs later. AHXR is a multifactorial process in which natural and elicited antibodies may play roles, possibly in conjunction with complement, coagulation factors, and white blood cells. A main target appears to be the microvasculature which, in kidney grafts, is associated with a glomerular thrombotic microangiopathy. It is not clear to what extent species‐specific physiologic disparities in complement and coagulation processes may play a role, separate from antibody‐initiated processes. As rejection of solid organ xenografts is currently from AHXR, ACXR has not yet received close attention. In addition to intragraft rejection events, systemic complications following host–graft interactions have emerged, including (often fatal) consumptive coagulopathy and immune complex disease. It is anticipated that rejection processes will change when pigs with new genetic modifications become available. For instance, the precise role of natural antibodies to Galα1,3Gal will be able to be distinguished from other factors when pigs that lack the target antigen are available, and their organs can be evaluated in large animal xenotransplantation models.
- 10 June 2003
- Published by Wiley in Xenotransplantation
- Vol. 10 (4) , 293-299
Pathology of xenograft rejection: a commentary
Trends in solid organ xenograft pathology are presented, with the focus on pig‐to‐nonhuman primate models. A simplified classification of rejection is followed, including hyperacute rejection (HAR), acute humoral xenograft rejection (AHXR), and acute cellular xenograft rejection (ACXR). The main components in HAR are natural xenoreactive antibodies in combination with complement activation. This is evident from the prevention of HAR in recipients in whom either antibodies or complement activation is depleted or inhibited. However, these strategies generally fail to prevent AHXR, which occurs later. AHXR is a multifactorial process in which natural and elicited antibodies may play roles, possibly in conjunction with complement, coagulation factors, and white blood cells. A main target appears to be the microvasculature which, in kidney grafts, is associated with a glomerular thrombotic microangiopathy. It is not clear to what extent species‐specific physiologic disparities in complement and coagulation processes may play a role, separate from antibody‐initiated processes. As rejection of solid organ xenografts is currently from AHXR, ACXR has not yet received close attention. In addition to intragraft rejection events, systemic complications following host–graft interactions have emerged, including (often fatal) consumptive coagulopathy and immune complex disease. It is anticipated that rejection processes will change when pigs with new genetic modifications become available. For instance, the precise role of natural antibodies to Galα1,3Gal will be able to be distinguished from other factors when pigs that lack the target antigen are available, and their organs can be evaluated in large animal xenotransplantation models.
- 1 October 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (7) , 951-960
Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD
FTY720 is a novel immunomodulator with a unique mechanism of action, i.e. chemokine-dependent lymphocyte homing into secondary lymphoid organs associated with profound lymphocyte depletion in blood. We investigated its efficacy, either FTY720 alone or together with cyclosporine or the rapamycin derivative rapamycin derivative (RAD), in cynomolgus monkey kidney allotransplantation. Life-supporting allotransplantation was performed in bilaterally nephrectomized hosts. Compounds were given once daily by oral gavage. Monitoring was done by serum creatinine and urea, and rejection was concluded when values exceeded 500 μmol/L and 50 mmol/L, respectively (5–6 times the upper limit of reference values). Rejection was confirmed by graft histology. The termination point was set to 100 days after transplantation. In addition, animals were monitored for 24 hr drug concentrations and thorough inspection of potential adverse side effects. FTY720 given alone at 3.0 mg/kg per day prolonged rejection-free survival (33–85 days, mean 24 hr concentration between 54 and 66 ng/mL [n=3]), but it was not efficacious at a 0.3 mg/kg per day dose. For cyclosporine alone, 30 mg/kg per day during maintenance was efficacious (average concentration above 100 ng/mL, historical data from our group), and for RAD alone 0.75 mg/kg per day (concentration above 10 ng/mL). Efficacious FTY720-cyclosporine-A (CsA) or FTY720-RAD combinations were established using 0.1–0.3 mg/kg per day FTY720, 10–30 mg/kg per day cyclosporine, and/or 0.25–0.50 mg/kg per day RAD. Compared with single-compound treatment, FTY720 effective doses and 24 hr trough concentrations were at least tenfold lower in combination treatment and those of cyclosporine and RAD about twofold lower, indicative of effective synergy between the compounds. Already at the lowest FTY720 dose tested (0.03 mg/kg per day), there was a profound lymphocyte depletion down to about 30% of pretransplant values, which further increased at the highest dose (3.0 mg/kg per day, to about 14% of pretransplant values). Lymphocyte depletion was reflected by a decrease in T and B subpopulations. FTY720 is an effective immunosuppressant in prevention of acute kidney allograft rejection in cynomolgus monkeys and synergizes with cyclosporine and/or RAD in yielding rejection-free allograft survival.
- 1 October 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (7) , 951-960
Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD
FTY720 is a novel immunomodulator with a unique mechanism of action, i.e. chemokine-dependent lymphocyte homing into secondary lymphoid organs associated with profound lymphocyte depletion in blood. We investigated its efficacy, either FTY720 alone or together with cyclosporine or the rapamycin derivative rapamycin derivative (RAD), in cynomolgus monkey kidney allotransplantation. Life-supporting allotransplantation was performed in bilaterally nephrectomized hosts. Compounds were given once daily by oral gavage. Monitoring was done by serum creatinine and urea, and rejection was concluded when values exceeded 500 μmol/L and 50 mmol/L, respectively (5–6 times the upper limit of reference values). Rejection was confirmed by graft histology. The termination point was set to 100 days after transplantation. In addition, animals were monitored for 24 hr drug concentrations and thorough inspection of potential adverse side effects. FTY720 given alone at 3.0 mg/kg per day prolonged rejection-free survival (33–85 days, mean 24 hr concentration between 54 and 66 ng/mL [n=3]), but it was not efficacious at a 0.3 mg/kg per day dose. For cyclosporine alone, 30 mg/kg per day during maintenance was efficacious (average concentration above 100 ng/mL, historical data from our group), and for RAD alone 0.75 mg/kg per day (concentration above 10 ng/mL). Efficacious FTY720-cyclosporine-A (CsA) or FTY720-RAD combinations were established using 0.1–0.3 mg/kg per day FTY720, 10–30 mg/kg per day cyclosporine, and/or 0.25–0.50 mg/kg per day RAD. Compared with single-compound treatment, FTY720 effective doses and 24 hr trough concentrations were at least tenfold lower in combination treatment and those of cyclosporine and RAD about twofold lower, indicative of effective synergy between the compounds. Already at the lowest FTY720 dose tested (0.03 mg/kg per day), there was a profound lymphocyte depletion down to about 30% of pretransplant values, which further increased at the highest dose (3.0 mg/kg per day, to about 14% of pretransplant values). Lymphocyte depletion was reflected by a decrease in T and B subpopulations. FTY720 is an effective immunosuppressant in prevention of acute kidney allograft rejection in cynomolgus monkeys and synergizes with cyclosporine and/or RAD in yielding rejection-free allograft survival.
- 1 May 2002
- Published by Elsevier in Transplant Immunology
- Vol. 9 (2-4) , 187-195
Mycophenolate sodium: tolerability and efficacy in transplantation in the rat
- 1 May 2002
- Published by Elsevier in Transplant Immunology
- Vol. 9 (2-4) , 187-195
Mycophenolate sodium: tolerability and efficacy in transplantation in the rat
- 1 April 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 73 (7) , 1146-1151
Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors
Cynomolgus monkeys or baboons received under immunosuppression kidney or heart grafts from pigs transgenic for human decay-accelerating factor (hDAF) or from control pigs. Hyperacute rejection (HAR) is often difficult to differentiate from nonimmunological causes of organ or recipient dysfunction (NIC), and therefore, a thorough pathology review of all cases with 0–4 days survival (inclusive) was conducted. Pathology slides were blinded and together with limited clinical data reviewed by two pathologists. After unblinding, data were compared with the original diagnosis made during the course of the program, and a final diagnosis was reached considering the complete clinical dataset. Life-supporting kidney transplantation was performed in 245 cynomolgus monkeys (234 hDAF, 11 controls), of which 102 cases had 0–4 day survival. None of the hDAF cases showed HAR, whereas this occurred in 27% of controls (P <10−6). Heterotopic heart transplantation was performed in 65 monkeys (57 hDAF, 8 controls), of which 41 cases had 0–4 day survival. HAR was observed in 7% of hDAF cases and in 57% of controls (P =0.002). Heterotopic heart transplantation in baboons was performed in 33 animals (28 hDAF, 5 controls), of which 15 cases had 0–4 day survival. HAR was observed in 11% of hDAF cases and in 20% of controls. Sixteen baboons were subjected to orthotopic heart transplantation, all from hDAF donors, out of which eight survived 0–4 days. The incidence of HAR was 6%. In the largest series of pig-to-primate solid organ transplants performed thus far, the presence of the hDAF transgene fully prevents HAR of cynomolgus monkey kidney transplants and partially inhibits HAR of heart grafts in cynomolgus monkeys or baboons. The incidence of HAR in control grafts is significantly higher.
- 1 April 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 73 (7) , 1146-1151
Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors
Cynomolgus monkeys or baboons received under immunosuppression kidney or heart grafts from pigs transgenic for human decay-accelerating factor (hDAF) or from control pigs. Hyperacute rejection (HAR) is often difficult to differentiate from nonimmunological causes of organ or recipient dysfunction (NIC), and therefore, a thorough pathology review of all cases with 0–4 days survival (inclusive) was conducted. Pathology slides were blinded and together with limited clinical data reviewed by two pathologists. After unblinding, data were compared with the original diagnosis made during the course of the program, and a final diagnosis was reached considering the complete clinical dataset. Life-supporting kidney transplantation was performed in 245 cynomolgus monkeys (234 hDAF, 11 controls), of which 102 cases had 0–4 day survival. None of the hDAF cases showed HAR, whereas this occurred in 27% of controls (P <10−6). Heterotopic heart transplantation was performed in 65 monkeys (57 hDAF, 8 controls), of which 41 cases had 0–4 day survival. HAR was observed in 7% of hDAF cases and in 57% of controls (P =0.002). Heterotopic heart transplantation in baboons was performed in 33 animals (28 hDAF, 5 controls), of which 15 cases had 0–4 day survival. HAR was observed in 11% of hDAF cases and in 20% of controls. Sixteen baboons were subjected to orthotopic heart transplantation, all from hDAF donors, out of which eight survived 0–4 days. The incidence of HAR was 6%. In the largest series of pig-to-primate solid organ transplants performed thus far, the presence of the hDAF transgene fully prevents HAR of cynomolgus monkey kidney transplants and partially inhibits HAR of heart grafts in cynomolgus monkeys or baboons. The incidence of HAR in control grafts is significantly higher.
- 15 March 2002
- Published by Wiley in Xenotransplantation
- Vol. 9 (2) , 135-147
Anti‐pig antibody levels in naïve baboons and cynomolgus monkeys
Anti‐pig antibodies (APA) were analysed in serum from 28 naïve wild‐caught baboons (originating from Kenya) and 31 naïve captive‐bred cynomolgus monkeys (13 from the Philippines and 18 from Mauritius), using a haemolytic assay with pig erythrocytes (APA), flow cytometry on the porcine lymphoma T‐cell cell line L35, and enzyme linked immunosorbent assay (ELISA) using α‐Gal type II and type VI antigen. This was extended in baboon samples by the evaluation in two laboratories (Imutran, Cambridge, UK and Immerge, Boston, USA), and by antibody absorption using either immobilized α‐Gal type II or α‐Gal type VI. Anti‐porcine antibodies were demonstrated in all assays with substantial variability within and between the three non‐human primate groups. Immunoglobulin (Ig)M antibody levels tended to be similar to or higher than those in a pooled normal human standard serum while IgG levels tended to be lower. Highest antibody levels were recorded in Mauritius cynomolgus monkeys. There were statistically significant correlations between assays for IgM or IgG class anti‐Gal antibodies using either α‐Gal type II or α‐Gal type VI as antigen, both for different assays and two laboratories involved. Also, significant correlations were observed between the anti‐Gal and L35 binding assays. Baboon sera before and after absorption to immobilized α‐Gal type II or type VI were analysed for anti‐Gal type VI or type II antibody: levels were almost undetectable indicating that most anti‐Gal antibodies react to epitopes shared between α‐Gal type II and type VI oligosaccharides. Finally, the relation between APA and outcome of porcine heart xenotransplantation in cynomolgus monkeys and baboons showed no apparent relation between pre‐transplant APA levels and the occurrence of hyperacute rejection (HAR) when compared with non‐immunological cause of organ/recipient dysfunction or acute humoral xenograft rejection during the first 4 days post‐transplantation or survival exceeding 4 days post‐transplantation.
- 15 March 2002
- Published by Wiley in Xenotransplantation
- Vol. 9 (2) , 135-147
Anti‐pig antibody levels in naïve baboons and cynomolgus monkeys
Anti‐pig antibodies (APA) were analysed in serum from 28 naïve wild‐caught baboons (originating from Kenya) and 31 naïve captive‐bred cynomolgus monkeys (13 from the Philippines and 18 from Mauritius), using a haemolytic assay with pig erythrocytes (APA), flow cytometry on the porcine lymphoma T‐cell cell line L35, and enzyme linked immunosorbent assay (ELISA) using α‐Gal type II and type VI antigen. This was extended in baboon samples by the evaluation in two laboratories (Imutran, Cambridge, UK and Immerge, Boston, USA), and by antibody absorption using either immobilized α‐Gal type II or α‐Gal type VI. Anti‐porcine antibodies were demonstrated in all assays with substantial variability within and between the three non‐human primate groups. Immunoglobulin (Ig)M antibody levels tended to be similar to or higher than those in a pooled normal human standard serum while IgG levels tended to be lower. Highest antibody levels were recorded in Mauritius cynomolgus monkeys. There were statistically significant correlations between assays for IgM or IgG class anti‐Gal antibodies using either α‐Gal type II or α‐Gal type VI as antigen, both for different assays and two laboratories involved. Also, significant correlations were observed between the anti‐Gal and L35 binding assays. Baboon sera before and after absorption to immobilized α‐Gal type II or type VI were analysed for anti‐Gal type VI or type II antibody: levels were almost undetectable indicating that most anti‐Gal antibodies react to epitopes shared between α‐Gal type II and type VI oligosaccharides. Finally, the relation between APA and outcome of porcine heart xenotransplantation in cynomolgus monkeys and baboons showed no apparent relation between pre‐transplant APA levels and the occurrence of hyperacute rejection (HAR) when compared with non‐immunological cause of organ/recipient dysfunction or acute humoral xenograft rejection during the first 4 days post‐transplantation or survival exceeding 4 days post‐transplantation.
- 1 March 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 73 (6) , 881-889
Serum anti-pig antibodies as potential indicators of acute humoral xenograft rejection in pig-to-cynomolgus monkey kidney transplantation
Hyperacute rejection of solid organ pig xenografts in nonhuman primates has been overcome by using donors transgenic for human complement regulatory proteins, but grafts are still susceptible to humoral (antibody-mediated) rejection. We investigated whether circulating xenoreactive antibodies are a useful indicator of this xenograft rejection. Five assays were employed in a retrospective analysis on 20 selected cynomolgus monkey recipients of renal xenografts transgenic for human decay-accelerating factor, with survival between 4 and 60 days. The assays included hemolytic and hemagglutination assays and the measurement of immunoglobulin (Ig)G and IgM binding to porcine endothelial cells and leukocytes, and to the Galα1-3Gal trisaccharide (Gal) antigen. To assess non-Gal-directed antibodies, sera were absorbed with a Gal-coated resin. A predictive value was defined as an increase in antibody levels before a decline in graft failure (>20% increase in creatinine levels) and humoral rejection in graft pathology. Data on hemolytic anti-pig antibody correlated with those on IgM antibody to endothelial cells, leukocytes, and Gal. In absorbed sera IgM and IgG antibody to endothelial cells and leukocytes correlated with each other, indicative for an elicited antibody response to non-Gal antigens. Sixteen animals showed humoral rejection, and in all but two animals one or more assays was considered of predictive value. On the other hand, increased antibody levels were noted in two animals without signs of rejection in graft pathology and in two cases with cellular xenograft rejection. It is recommended to use multiple assays (preferably hemolytic, anti-Gal, and anti-endothelial cell) to be able to fully monitor the peripheral antibody responses in pig-to-primate xenograft recipients.
- 1 March 2002
- Published by Wolters Kluwer Health in Transplantation
- Vol. 73 (6) , 881-889
Serum anti-pig antibodies as potential indicators of acute humoral xenograft rejection in pig-to-cynomolgus monkey kidney transplantation
Hyperacute rejection of solid organ pig xenografts in nonhuman primates has been overcome by using donors transgenic for human complement regulatory proteins, but grafts are still susceptible to humoral (antibody-mediated) rejection. We investigated whether circulating xenoreactive antibodies are a useful indicator of this xenograft rejection. Five assays were employed in a retrospective analysis on 20 selected cynomolgus monkey recipients of renal xenografts transgenic for human decay-accelerating factor, with survival between 4 and 60 days. The assays included hemolytic and hemagglutination assays and the measurement of immunoglobulin (Ig)G and IgM binding to porcine endothelial cells and leukocytes, and to the Galα1-3Gal trisaccharide (Gal) antigen. To assess non-Gal-directed antibodies, sera were absorbed with a Gal-coated resin. A predictive value was defined as an increase in antibody levels before a decline in graft failure (>20% increase in creatinine levels) and humoral rejection in graft pathology. Data on hemolytic anti-pig antibody correlated with those on IgM antibody to endothelial cells, leukocytes, and Gal. In absorbed sera IgM and IgG antibody to endothelial cells and leukocytes correlated with each other, indicative for an elicited antibody response to non-Gal antigens. Sixteen animals showed humoral rejection, and in all but two animals one or more assays was considered of predictive value. On the other hand, increased antibody levels were noted in two animals without signs of rejection in graft pathology and in two cases with cellular xenograft rejection. It is recommended to use multiple assays (preferably hemolytic, anti-Gal, and anti-endothelial cell) to be able to fully monitor the peripheral antibody responses in pig-to-primate xenograft recipients.
- 1 February 2002
- Published by Wiley in European Surgery
- Vol. 34 (1) , 58-64
Solid Organ Xenotransplantation: Experience in the Pig-to-Primate Transplantation Model
- 1 February 2002
- Published by Wiley in European Surgery
- Vol. 34 (1) , 58-64
Solid Organ Xenotransplantation: Experience in the Pig-to-Primate Transplantation Model